

Nexcyon Pharmaceuticals Ltd
Bank Barn
How Mill
Brampton
Cumbria
CA8 9JY
United Kingdom

Date: 30 June 2014

Veterinary Medicines and Inspections Unit
European Medicines Agency
7 Westferry Circus
Canary Wharf
London
E14 4HB
United Kingdom

Subject: Withdrawal of Enthryv EMEA/V/C/002808/0000

Dear Sirs,


I would like to inform you that, at this point of time, Nexcyon Pharmaceuticals Ltd, has taken the decision to withdraw the application for Marketing Authorisation of Enthryv 18.75 mg transdermal solution for cats, Enthryv 37.5 mg transdermal solution for cats and Enthryv 56.25 mg transdermal solution for cats, containing thiamazole, which was intended to be used for 'treatment of hyperthyroidism in cats where compliance to an oral anti-thyroid therapy cannot be achieved'.

This withdrawal is based on the following reasons: the CVMP considers that the data provided do not allow the committee to conclude on a positive benefit risk balance

We reserve the right to make further submissions at a future date in this or other therapeutic indication(s)/target species, if applicable.

I agree for this letter to be published on the EMA website.

Yours faithfully,

A large black rectangular box used to redact the signature of the representative of Nexcyon Pharmaceuticals Ltd.

On Behalf of Nexcyon Pharmaceuticals Ltd